2m 2m 2m 2m 2m 2m 2m
Ocular Therapeut (OCUL)
NASDAQ
$10.27+$0.30 (+3.04%)
Price as of Jun 23, 2026 7:14 PM EDT- $2.2BMarket Cap
- 19.12%1-Year Change
- BiotechnologyIndustry
Ocular Therapeut (OCUL)
$10.27+$0.30 (+3.04%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 51.8M -18.67% | 63.7M +9.03% | 58.4M +13.49% | 51.5M +18.32% | |
Cost of Revenue | 6.6M +16.85% | 5.6M +6.53% | 5.3M +16.32% | 4.5M +3.04% | |
Gross Profit | 45.2M -22.11% | 58.1M +9.28% | 53.2M +13.22% | 47.0M +20.04% | |
Sales and Marketing Expense | 53.9M +29.65% | 41.6M +2.57% | 40.5M +1.57% | 39.9M +13.45% | |
Research and Development Expense | -197.1M +54.42% | -127.6M +109.05% | -61.1M +14.20% | -53.5M +6.75% | |
Depreciation and Amortization Expense | 4.3M +14.18% | 3.8M +26.92% | 3.0M +41.44% | 2.1M -12.89% | |
Total Operating Expenses | 322.0M +36.71% | 235.5M +67.23% | 140.8M +8.20% | 130.1M +7.07% | |
Operating Profit | -270.0M +57.19% | -171.8M +108.52% | -82.4M +4.74% | -78.7M +0.79% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -887,000 0.00% | -887,000 -92.18% | -11.3M +61.46% | -7.0M +5.26% | |
Interest Income and Expense and Net | -887,000 0.00% | -887,000 -92.18% | -11.3M +61.46% | -7.0M +5.26% | |
Total Nonoperating Income and Expense | 4.1M +118.77% | -21.7M -1,419.87% | 1.6M -78.39% | 7.6M -89.35% | |
Income before Taxes | -270.0M +57.19% | -171.8M +108.52% | -82.4M +4.74% | -78.7M +0.79% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -265.9M +37.43% | -193.5M +139.68% | -80.7M +13.65% | -71.0M +984.05% | |
Net Income from Continuing Operations Applicable to Common | -265.9M +37.43% | -193.5M +139.68% | -80.7M +13.65% | -71.0M +984.05% | |
Basic EPS and Net Income | -1.42 +16.39% | -1.22 +20.79% | -1.01 +9.78% | -0.92 +922.22% | |
Diluted EPS and Net Income | -1.42 +16.39% | -1.22 +19.61% | -1.02 +5.15% | -0.97 -1.02% | |
Basic Weighted Average Shares | 187.2M +18.31% | 158.3M +98.26% | 79.8M +3.84% | 76.9M +0.63% | |
Diluted Weighted Average Shares | 187.2M +18.31% | 158.3M +84.90% | 85.6M +3.57% | 82.6M +0.59% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 737.1M +87.98% | 392.1M +100.25% | 195.8M +91.40% | 102.3M -37.68% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 737.1M +87.98% | 392.1M +100.25% | 195.8M +91.40% | 102.3M -37.68% | |
Total Current Assets | 782.1M +77.36% | 441.0M +89.89% | 232.2M +79.16% | 129.6M -32.24% | |
Accumulated Depreciation | 27.5M +16.45% | 23.6M +16.64% | 20.3M +17.26% | 17.3M +13.62% | |
Property and Plant and Equipment and Net | 19.7M +109.56% | 9.4M -20.02% | 11.7M +19.11% | 9.9M +41.69% | |
Total Long-Term Assets | 19.7M +109.56% | 9.4M -20.02% | 11.7M +19.11% | 9.9M +41.69% | |
Total Assets | 808.1M +76.46% | 457.9M +81.68% | 252.1M +68.84% | 149.3M -27.14% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 25.0M 0.00% | 25.0M 0.00% | 25.0M 0.00% | 25.0M +201.57% | |
Total Current Liabilities | 50.8M +22.86% | 41.4M +18.51% | 34.9M +11.15% | 31.4M +19.20% | |
Total Long-Term Debt | 71.3M -8.12% | 77.6M +3.63% | 74.9M +38.73% | 54.0M +5.00% | |
Total Long-Term Liabilities | 887,000 +529.08% | 141,000 +30.56% | 108,000 +16.13% | 93,000 -99.85% | |
Total Liabilities | 153.7M +7.82% | 142.6M -11.40% | 160.9M +41.28% | 113.9M -2.55% | |
Retained Earnings | -1.2B +29.84% | -891.1M +27.74% | -697.6M +13.09% | -616.8M +13.02% | |
Total Stockholders Equity | 654.3M +107.49% | 315.3M +246.03% | 91.1M +157.59% | 35.4M -59.80% | |
Total Shares Outstanding | 215.9M +36.88% | 157.7M +37.22% | 115.0M +48.91% | 77.2M +0.61% | |
Cash Flow | |||||
Cash from Operating Activities | -204.9M +52.13% | -134.7M +91.75% | -70.2M +17.84% | -59.6M -9.07% | |
Capital Expenditures | 12.0M +832.45% | 1.3M -78.84% | 6.1M +63.85% | 3.7M +211.14% | |
Cash from Investing Activities | -11.9M +822.36% | -1.3M -78.84% | -6.1M +63.85% | -3.7M +211.14% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 561.7M +69.14% | 332.1M +95.56% | 169.8M +11,580.06% | 1.5M -49.00% | |
Financials Ratio | |||||
Gross Margin | 87.31% -4.23% | 91.17% +0.23% | 90.96% -0.24% | 91.18% +1.45% | |
Operating Margin | -521.04% +93.28% | -269.57% +91.24% | -140.96% -7.71% | -152.74% -14.81% | |
Return on Assets | -42.01% -22.93% | -54.51% +35.49% | -40.23% +0.29% | -40.11% +1,328.63% | |
Return on Equity | -54.85% -42.39% | -95.21% -25.40% | -127.64% +10.84% | -115.16% +1,341.80% | |
Revenue Growth | -18.67% -306.71% | 9.03% -33.05% | 13.49% -26.33% | 18.32% -87.80% | |
Current Ratio | 15.39 +44.36% | 10.66 +60.23% | 6.66 +61.18% | 4.13 -43.16% | |
Cash Ratio | 14.51 +53.00% | 9.48 +68.98% | 5.61 +72.20% | 3.26 -47.72% | |
Debt-to-Equity Ratio | 0.15 -54.78% | 0.33 -70.31% | 1.10 -50.90% | 2.23 +229.03% | |
Debt-to-Assets Ratio | 0.12 -46.81% | 0.22 -43.47% | 0.40 -25.09% | 0.53 +81.54% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow